Researchers developed a CRISPR-based system that increases mitochondrial production in heart cells. Early tests in human cells, heart tissue, and animal models showed promising results, suggesting ...
After a heart attack, the heart struggles to recoup and maintain energy. One third of patients develop heart failure as a ...
The company got into the game by partnering with smaller drugmakers in this field, most notably CRISPR Therapeutics. The two ...
CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline how the ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...
Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...
One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results